Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Elbit Imaging Ltd. Announces Swiss Team Uses InSightec's ExAblate(R) 4000 Brain System To Treat Patients With Functional Brain Disorders
Elbit Imaging Ltd. (TASE: EMIT, Nasdaq: EMITF), announced that, its subsidiary (in which EI holds indirectly approximately 58.34%, InSightec Ltd., announced that a team at the University Children"s Hospital Zurich has completed a feasibility study testing the use of non-invasive transcranial MR-guided focused ultrasound surgery (TcMRgFUS) for the treatment of neuropathic pain. Ten adult patients diagnosed with chronic neuropathic pain successfully underwent non-invasive deep brain ablation surgery (central lateral thalamotomy) with transcranial TcMRgFUS and showed improvement in pain scores and reduction of pain medication with no adverse effects at three months follow-up. This is the first study in the world to test non-invasive transcranial focused ultrasound as a treatment modality for functional brain disorders.
generic viagra online
AEterna Zentaris To Report Data From Safety Study Of Phase 3 Program In Benign Prostatic Hyperplasia With Cetrorelix Ahead Of Schedule
AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 program in benign prostatic hyperplasia (BPH) with its lead endocrinology compound, cetrorelix pamoate, is scheduled to be completed at the end of this week. Therefore, data analysis and reporting will be brought forward from the scheduled fourth quarter into the third quarter of 2009, and will follow the disclosure of results from the first double-blind placebo controlled efficacy study (study 033). BPH is a benign enlargement of the prostate, affecting more than 20 million men in the U.S. alone.
News of the day
Symposium & Live Announcement Of Genetics And Neuroscience Prize Recipients: Gruber Prize Program 10th Anniversary
July 1, 2009
Endocrinology

FDA Urges Consumers Not To Purchase Or Use Certain Gel-Filled Teethers

Luv N" Care Ltd. of Monroe, La., is initiating a nationwide recall of gel-filled teethers with the brand names "Nuby," "Cottontails" and "Playschool," because the liquid inside the gel-filled teethers has been found to contain Bacillus subtilis and Bacillus circulans bacteria in the gel. Although these bacteria generally do not cause illness in adults, infants and children with weakened immune systems can experience stomach pain, vomiting, diarrhea, and uncommonly more serious disease, if the teether becomes punctured and they ingest the liquid gel. Consumers who have teethers with the brand names and UPC Codes listed below should immediately stop using them and discard or return them to the place of purchase for a full refund. The recall includes the following products: UPC code - Brand Name 48526-00451 - Nuby 48526-00452 - Nuby 48526-00453 - Nuby 48526-00454 - Nuby 48526-00455 - Nuby 48526-00459 - Nuby 48526-00467 - Nuby 48526-00472 - Nuby 48526-00473 - Nuby 48526-00482 - Nuby 48526-00483 - Nuby 48526-00487 - Nuby 48526-00490 - Nuby 48526-00519 - Nuby 48526-00521 - Nuby 41520-87115 - Cottontails 50428-91511 - Playschool 41520-91660 - Cottontails The firm voluntarily recalled the products after learning that the FDA found Bacillus subtilis and Bacillus circulans in the gel in samples from two lots collected by the FDA. No illnesses have been reported to date. The company distributed the products through retail outlets nationwide. The products have also been found to be marketed on the Internet. The products are packaged in a plastic bubble on a printed card and can be identified by the UPC Codes listed above. The company has ceased production and distribution of the products and is notifying its distributors to return the products. Consumers are urged to return the products to the place of purchase for a full refund. Consumers with questions may contact the company at 1-800-256-2399 ext. 3106 between 8 a.m. and 5 p.m. central time. Adverse reactions experienced with the use of this product may be reported to the FDA"s MedWatch Adverse Event Reporting program either online, by regular mail or by fax. - Online: http://www.fda.gov/medwatch/report.htm - Regular Mail: use postage-paid FDA form 3500 available at: http://www.fda.gov/MedWatch/getforms.htm. Mail to MedWatch 5600 Fishers Lane, Rockville, MD 20852-9787 - Fax: 1-800-FDA-0178 U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009